Relmada Therapeutics (RLMD) Tops Q4 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
• Morgan Stanley Downgrades Melco Resorts (MLCO) to Equalweight